{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:53:11Z","timestamp":1790837591037,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1080\/14653240310002199","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T18:38:11Z","timestamp":1062095891000},"page":"279-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role and activities of the ISCT Regulatory Affairs Committee"],"prefix":"10.1016","volume":"5","author":[{"given":"L.L.","family":"Kelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1080\/14653240310002199_bib1","first-page":"52696","volume":"64","year":"1999","journal-title":"[Proposed rule.] Fed Reg"},{"key":"10.1080\/14653240310002199_bib2","first-page":"66621","volume":"65","year":"2000","journal-title":"[Final rule.] Fed Reg"},{"key":"10.1080\/14653240310002199_bib3","first-page":"5447","volume":"66","year":"2001","journal-title":"[Final rule.] Fed Reg"},{"key":"10.1080\/14653240310002199_bib4","first-page":"1508","volume":"66","year":"2001","journal-title":"[Proposed rule.] Fed Reg"},{"key":"10.1080\/14653240310002199_bib5","unstructured":"Good manufacturing practice guidance for active pharmaceutical ingredients. [Guidance, 2001.] www.fda.gov\/cber\/guidelines.htm visited 23rd May 2003."},{"key":"10.1080\/14653240310002199_bib6","unstructured":"General principles of software validation. [Guidance, 2002.] www.fda.gov\/cber\/guidelines.htm visited 23rd May 2003."},{"key":"10.1080\/14653240310002199_bib7","unstructured":"Preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant CreutzfeldtJakob disease (vCJD) by human cells, tissues and cellular and tissue-based productS. [Guidance, 2002.] www.fda.gov\/cber\/guidelines.htm visited 23rd May 200l."},{"key":"10.1080\/14653240310002199_bib8","unstructured":"Streamlining the donor interview process: recommendations for self-administered questionnaires. [Guidance, 2002.] www.fda.gov\/cber\/guidelines.htm visited 23rd May 200l."},{"key":"10.1080\/14653240310002199_bib9","unstructured":"Validation of procedures for processing of human tissues intended for transplantation. [Guidance, 2002.] www.fda.gov\/cber\/guidelines.htm visited 23rd May 2003."},{"key":"10.1080\/14653240310002199_bib10","unstructured":"Electtonic records; electronic signatures and maintenance of electronic records. [Guidance, 2002.] www.fdagov\/cber\/guidelines.htm visited 23rd May 2003."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324903711517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324903711517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:08:48Z","timestamp":1761430128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324903711517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003]]}},"alternative-id":["S1465324903711517"],"URL":"https:\/\/doi.org\/10.1080\/14653240310002199","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role and activities of the ISCT Regulatory Affairs Committee","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1080\/14653240310002199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}